Slide background

Slide background
Slide background
Slide background

Loading Events
New York Cancer Genomics Research Network Meeting

5:00 PM — 8:00 PM

Moderated by Harold Varmus, MD

See New York Genome Center’s lecture series, events and archives VIEW FULL CALENDAR





To advance collaborative efforts on cancer genomics, the New York Genome Center (NYGC) hosts meetings on the first Tuesday of every month to bring together leading cancer researchers, clinicians and postdocs from the NYGC’s Institutional Founding Members and other key academic institutions. The organizers include Drs. Harold Varmus (NYGC & Weill Cornell Medicine), Marcin Imielinski (NYGC &Weill Cornell Medicine), Ross Levine (Memorial Sloan Kettering Cancer Center) and Sohail Tavazoie (The Rockefeller University). 


Tuesday, October 2, 2018
5:00 PM – 7:00 PM: Speaker Presentations and Q&A
7:00 PM – 8:00 PM: Hors d’oeuvres & Networking


New York Genome Center
101 Avenue of the Americas, 1st Floor Auditorium







Harold Varmus, MD 

Senior Associate Core Member
New York Genome Center



Lewis Thomas University Professor of Medicine
Weill Cornell Medicine











Alejandro Chavez, MD, PhD
Assistant Professor of Pathology and Cell Biology
Columbia University


High-Throughput Technologies to Decipher Biology


Alejandro (Alex) Chavez, M.D., Ph.D. is an Assistant Professor of Pathology and Cell Biology at Columbia University. Alex’s laboratory employs Cas9-based tools for the programmable control of DNA and RNA on genome-wide scales.  His lab has generated methods that endow Cas9 with single nucleotide specificity and that enable facile genome modification, activation, or repression, both alone and in any desired combination. To facilitate the adaptation of their tools, his group makes all of their published reagents available by depositing them within Addgene (to date 700+ research groups have requested their reagents), as his group believes the value of their technology is more within the research it enables than in the individual publications they produce.


To learn more about Dr. Chavez’s research, visit his lab page.





Evripidis Gavathiotis, PhD
Associate Professor
Department of Biochemistry
Department of Medicine
Experimental Therapeutics Program
Albert Einstein Cancer Center


“Novel Targeting of BCL-2 Family Protein Interactions in Cancer”


Evripidis (Evris) Gavathiotis, Ph.D. is an Associate Professor of Biochemistry and Medicine at Albert Einstein College of Medicine and faculty member of the Albert Einstein Cancer Center, the Institute for Aging Research, the Gottesman Institute for Stem Cell Biology and Regenerative Medicine and the Wilf Family Cardiovascular Research Institute. He is conducting innovative research on mechanisms of protein interactions in cell death and cell survival signaling that cause cancer and other aging-associated diseases and the discovery of small molecule modulators with the goal of developing new therapeutics. Dr. Gavathiotis has co-authored numerous scientific publications and United States patent applications and is a co-founder of two biotechnology companies. He has received many awards throughout his career including the Sidney Kimmel Scholar Award, the 2014 Young Chemical Biologist Award and the Pershing Square Sohn Prize. Dr. Gavathiotis performed postdoctoral research at Rockefeller University and the Dana-Farber Cancer Institute and was a junior faculty at Harvard Medical School. He received his Ph.D. in Biological Chemistry from the University of Nottingham.


To learn more about Dr. Gavathiotis’ research, visit his profile page.





Anne Bowcock, PhD
Norman Orentreich, MD Professor of Dermatology Research
Departments of Oncological Sciences, Dermatology and Genetics & Genome Sciences
Icahn School of Medicine at Mount Sinai


“Genetic Analysis of Uveal Melanoma”


Uveal melanoma is a rare and frequently devastating cancer of the adult eye that leads to metastasis in about 50% of cases. To date there are no effective treatments for this tumor type. Understanding the molecular alterations is central to developing new therapies. Dr. Bowcock was the first to identify BRCA1 associated protein 1 (BAP1) as a metastasis suppressor of this cancer. She later went on to identify SF3B1 as a second gene that is mutated in other uveal melanomas with less chance of metastasis. Her more recent studies have examined the functional role of BAP1, revealed PRAME gene as a biomarker of metastasis in some uveal melanomas and involved a comprehensive analysis of genomic alterations in UM, integrating data from copy number, transcriptome analysis and exome sequencing. Together with JW Harbour, Dr. Bowcock was awarded a patent on BAP1 and use of mutations in this gene as a predictor of metastasis. These findings are being incorporated into the diagnosis of uveal melanoma in the clinic, and she is examining the functional consequences of genomic and genetic alterations in order to develop novel targeted therapies for this tumor type.


To learn more about Dr. Bowcock’s research, visit her profile page.


Discussion and Q&A

Moderated by Harold Varmus, MD
Discussion and Q&A will take place after each speaker presents.
These meetings are held on the first Tuesday of each month and are intended for principal investigators in the New York region and their trainees.
Any questions on this event, contact



  • +
    The New York Genome Center’s Evening Talks events feature distinguished experts from around the world sharing genomic insights and research. They are intended to showcase and explain high science to the non-scientific community. Speakers present the latest research findings and explain its implication for helping improve clinical care for a wide array of serious diseases. The lecture is followed by a lively question-and-answer session and a post-event reception of hors d’oeuvres and cocktails. These popular free public events are held in the Center’s state-of-the-art ground-floor auditorium starting at 6:30 pm. The Evening Talks Series is sponsored by The New York Community Trust – Pyewacket Fund.

  • +